市場調査レポート
商品コード
1462270
NE-3107市場:市場規模、予測、新たな洞察-2032年NE-3107 Market Size, Forecast, and Emerging Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
NE-3107市場:市場規模、予測、新たな洞察-2032年 |
出版日: 2024年04月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
NE-3107は、炎症性ERKシグナルを選択的に阻害することで、神経炎症を抑制し、炎症に起因するインスリン抵抗性やその他の主要な病的炎症カスケードを抑制する経口投与の新規低分子化合物です。
最近完了したパーキンソン病治療薬NE3107の第I/II相臨床試験では良好な結果が得られており、パーキンソン病第II相臨床試験のデータが採択されたことから、2023年に開催されるアルツハイマー病とパーキンソン病に関する国際会議でこの結果を発表する予定です。BioVieはSUNRISE-1のピボタル第IIb相試験を2023年第3四半期に開始する予定であり、SUNRISE-2はピボタル第III相試験を2024年第1四半期後半に開始する可能性があります。
今後数年間で、パーキンソン病の市場シナリオは、世界中の広範な調査と医療費の増加により変化します。各社は、病態を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、NE-3107の優位性に影響を与える可能性のある機会を模索しています。パーキンソン病に対する他の新興製品がNE-3107と厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。
当レポートでは、主要7ヶ国におけるパーキンソン病治療薬のNE-3107市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。
"NE-3107 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about NE-3107 for Parkinson's disease in the seven major markets. A detailed picture of the NE-3107 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the NE-3107 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NE-3107 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
NE-3107 is a novel orally administered small molecule that selectively inhibits the inflammatory ERK signaling and thereby reduces neuroinflammation, inhibit inflammation-driven insulin resistance, and other major pathological inflammatory cascades.
The recently completed Phase I/II trial of NE3107 for treating Parkinson's disease depicted positive results and the company will present these results at the International Conference on Alzheimer's and Parkinson's Diseases to be held in 2023 as the data from Phase II Parkinson's Disease trial is accepted for the presentation. BioVie plans to initiate the pivotal Phase IIb trial SUNRISE-1 in 3Q2023, and SUNRISE-2 is a potentially pivotal Phase III starting late 1Q2024.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
NE-3107 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of NE-3107 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.
The report provides the clinical trials information of NE-3107 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.